Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

PHASE3CompletedINTERVENTIONAL

Enrollment

365

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

August 31, 2004

Conditions

Peripheral Vascular Disease

Interventions

DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight

DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight